Also today, Trius Therapeutics (TSRX) said a phase 3 trial of its tedizolid phosphatetreatment for bacterial skin and skin structure infections met its primary endpoint.
Since the early 1980s, the EPA has included waste created from zinc phosphate processing on its list of FO19 hazardous wastes, which requires expensive additional treatment.